Other names for GLP-1 analogs include GLP-1 agonists, GLP-1 receptor agonists, and incretin mimetics
Kanakis, G
It is composed of three essential amino acids: cysteine, glycine, and glutamic acid
Distinguished researcher, Jill James PhD, of the Arkansas Children's Hospital Research Institute, developed this proprietary formulation
cagrilintide is being developed primarily for obesity
In addition, the compound did not trigger the nausea, malaise and gastrointestinal adverse effects commonly seen with many first-generation GLP-1 therapies, a distinction that could become increasingly significant as patient populations and adherence demands grow